CN106535924A - 阿尔茨海默病(ad)的治疗和预防 - Google Patents
阿尔茨海默病(ad)的治疗和预防 Download PDFInfo
- Publication number
- CN106535924A CN106535924A CN201580029876.1A CN201580029876A CN106535924A CN 106535924 A CN106535924 A CN 106535924A CN 201580029876 A CN201580029876 A CN 201580029876A CN 106535924 A CN106535924 A CN 106535924A
- Authority
- CN
- China
- Prior art keywords
- aluminum
- administered
- patient
- aluminum salt
- oxyhydroxide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
- A61K33/08—Oxides; Hydroxides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0007—Nervous system antigens; Prions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461985710P | 2014-04-29 | 2014-04-29 | |
| EP14166355.9 | 2014-04-29 | ||
| US61/985,710 | 2014-04-29 | ||
| EP14166355 | 2014-04-29 | ||
| PCT/EP2015/059337 WO2015165964A1 (en) | 2014-04-29 | 2015-04-29 | Treatment and prevention of alzheimer's disease (ad) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106535924A true CN106535924A (zh) | 2017-03-22 |
Family
ID=50555097
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201580029876.1A Pending CN106535924A (zh) | 2014-04-29 | 2015-04-29 | 阿尔茨海默病(ad)的治疗和预防 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US10646565B2 (enExample) |
| EP (1) | EP3137097B1 (enExample) |
| JP (1) | JP2017514831A (enExample) |
| KR (1) | KR102460465B1 (enExample) |
| CN (1) | CN106535924A (enExample) |
| AU (3) | AU2015254661A1 (enExample) |
| CA (1) | CA2946929A1 (enExample) |
| ES (1) | ES2953381T3 (enExample) |
| PL (1) | PL3137097T3 (enExample) |
| WO (2) | WO2015165964A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112672756A (zh) * | 2018-10-25 | 2021-04-16 | 基立福环球运营有限公司 | 低容量血浆置换用于治疗早期和中期的阿尔茨海默病的用途 |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106535924A (zh) | 2014-04-29 | 2017-03-22 | 阿费里斯股份公司 | 阿尔茨海默病(ad)的治疗和预防 |
| KR102506460B1 (ko) * | 2014-04-29 | 2023-03-03 | 어드밴티지 테라퓨틱스, 인코포레이티드 | 알츠하이머병(ad)의 치료 및 예방 |
| WO2015165966A1 (en) * | 2014-04-29 | 2015-11-05 | Affiris Ag | Treatment and prevention of alzheimer's disease (ad) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101043901A (zh) * | 2004-07-13 | 2007-09-26 | 阿法里斯研发有限责任公司 | 预防和治疗阿尔茨海默病的方法 |
| CN102834118A (zh) * | 2010-03-29 | 2012-12-19 | 诺华有限公司 | 包含与病毒样颗粒偶联的淀粉样β1-6肽及佐剂的组合物 |
| TW201345927A (zh) * | 2012-05-01 | 2013-11-16 | Affiris Ag | 組成物 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994016327A1 (en) * | 1993-01-14 | 1994-07-21 | Pollard Harvey B | Methods and compositions for blocking amyloid protein ion channels |
| TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US7964192B1 (en) * | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| US6905686B1 (en) * | 1997-12-02 | 2005-06-14 | Neuralab Limited | Active immunization for treatment of alzheimer's disease |
| US10383887B2 (en) * | 2008-02-20 | 2019-08-20 | New York University | Preventing and treating amyloid-beta deposition by stimulation of innate immunity |
| AT506820B1 (de) * | 2008-06-12 | 2011-07-15 | Affiris Forschungs Und Entwicklungs Gmbh | Vakzine gegen alzheimer-krankheit |
| AT506819B1 (de) * | 2008-06-12 | 2011-06-15 | Affiris Forschungs Und Entwicklungs Gmbh | Vakzin zur behandlung von alzheimer-krankheit |
| KR102506460B1 (ko) * | 2014-04-29 | 2023-03-03 | 어드밴티지 테라퓨틱스, 인코포레이티드 | 알츠하이머병(ad)의 치료 및 예방 |
| WO2015165966A1 (en) | 2014-04-29 | 2015-11-05 | Affiris Ag | Treatment and prevention of alzheimer's disease (ad) |
| CN106535924A (zh) | 2014-04-29 | 2017-03-22 | 阿费里斯股份公司 | 阿尔茨海默病(ad)的治疗和预防 |
-
2015
- 2015-04-29 CN CN201580029876.1A patent/CN106535924A/zh active Pending
- 2015-04-29 WO PCT/EP2015/059337 patent/WO2015165964A1/en not_active Ceased
- 2015-04-29 CA CA2946929A patent/CA2946929A1/en not_active Abandoned
- 2015-04-29 AU AU2015254661A patent/AU2015254661A1/en not_active Abandoned
- 2015-04-29 EP EP15720058.5A patent/EP3137097B1/en active Active
- 2015-04-29 US US15/307,714 patent/US10646565B2/en active Active
- 2015-04-29 WO PCT/EP2015/059355 patent/WO2015165974A1/en not_active Ceased
- 2015-04-29 JP JP2016565238A patent/JP2017514831A/ja active Pending
- 2015-04-29 PL PL15720058.5T patent/PL3137097T3/pl unknown
- 2015-04-29 ES ES15720058T patent/ES2953381T3/es active Active
- 2015-04-29 KR KR1020167033323A patent/KR102460465B1/ko active Active
-
2020
- 2020-03-17 US US16/821,557 patent/US11147873B2/en active Active
-
2021
- 2021-01-08 AU AU2021200093A patent/AU2021200093B2/en active Active
- 2021-09-23 US US17/482,579 patent/US20220062412A1/en active Pending
-
2024
- 2024-02-20 AU AU2024201099A patent/AU2024201099A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101043901A (zh) * | 2004-07-13 | 2007-09-26 | 阿法里斯研发有限责任公司 | 预防和治疗阿尔茨海默病的方法 |
| CN102834118A (zh) * | 2010-03-29 | 2012-12-19 | 诺华有限公司 | 包含与病毒样颗粒偶联的淀粉样β1-6肽及佐剂的组合物 |
| TW201345927A (zh) * | 2012-05-01 | 2013-11-16 | Affiris Ag | 組成物 |
Non-Patent Citations (2)
| Title |
|---|
| 潘欣: "《医学生物侦检与防护技术概论》", 31 July 2011, 军事医学科学出版社 * |
| 陈冠荣: "《化工百科全书》", 30 April 1996, 化学工业出版社 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112672756A (zh) * | 2018-10-25 | 2021-04-16 | 基立福环球运营有限公司 | 低容量血浆置换用于治疗早期和中期的阿尔茨海默病的用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2946929A1 (en) | 2015-11-05 |
| KR102460465B1 (ko) | 2022-10-27 |
| AU2015254661A1 (en) | 2016-11-10 |
| JP2017514831A (ja) | 2017-06-08 |
| EP3137097A1 (en) | 2017-03-08 |
| AU2024201099A1 (en) | 2024-03-14 |
| WO2015165964A8 (en) | 2017-02-09 |
| WO2015165964A1 (en) | 2015-11-05 |
| EP3137097C0 (en) | 2023-06-21 |
| US10646565B2 (en) | 2020-05-12 |
| EP3137097B1 (en) | 2023-06-21 |
| AU2021200093B2 (en) | 2024-03-07 |
| US20220062412A1 (en) | 2022-03-03 |
| WO2015165974A1 (en) | 2015-11-05 |
| AU2015254661A9 (en) | 2019-08-01 |
| US11147873B2 (en) | 2021-10-19 |
| ES2953381T3 (es) | 2023-11-13 |
| US20200338192A1 (en) | 2020-10-29 |
| AU2021200093A1 (en) | 2021-03-18 |
| PL3137097T3 (pl) | 2023-09-11 |
| KR20160145820A (ko) | 2016-12-20 |
| US20170056495A1 (en) | 2017-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2021200093B2 (en) | Treatment and prevention of alzheimer's disease (ad) | |
| US20240148782A1 (en) | Treatment and prevention of alzheimer's disease (ad) | |
| KR102388363B1 (ko) | 알츠하이머병(ad)의 치료 및 예방 | |
| WO2015165971A1 (en) | Treatment and prevention of alzheimer's disease (ad) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20170322 |
|
| WD01 | Invention patent application deemed withdrawn after publication |